Overview of Maxiostenil Plus

Property	Description
Active ingredient	Sodium Hyaluronate
Form	Viscoelastic Solution, Prefilled Syringe
Pharmacological Class	Viscosupplementation Agent / Rheumatologic Agent
General Purpose	Supports Joint Function and Mobility
Origin	Naturally derived (via Fermentation)

Maxiostenil Plus: Identity and Pharmacological Classification

Maxiostenil Plus is a prescription-only formulation classified as a viscosupplementation agent, which is a specialized type of Rheumatologic Agent and Antiartrósico (antiarthritic). This medication is specifically designed for direct intervention in the joint's mechanical environment. High molecular weight hyaluronic acid products are used as medical devices intended to restore the viscoelasticity of the synovial fluid. This approach is clinically recognized for providing localized support to the joint, distinguishing it from broad systemic anti-inflammatory treatments.

Composition, Origin, and Dosage Form

The active ingredient is Sodium Hyaluronate, the sodium salt of Hyaluronic acid (HA), a naturally occurring glycosaminoglycan. The substance is manufactured via a biological fermentation process, establishing its naturally derived origin. Hyaluronic acid is a key compound found in the synovial fluid, where it serves as a component for lubrication and shock absorption. Maxiostenil Plus is prepared as a sterile, concentrated viscoelastic solution typically containing 40 mg/2.0 mL of the active ingredient. This specialized single active ingredient product is contained in a prefilled syringe, intended for administration via **intra-articular injection.

General Purpose: How Maxiostenil Plus Supports Joint Function

The overarching purpose of Maxiostenil Plus is to support joint mechanics and mobility, typically applied in scenarios where a patient experiences reduced joint function due to fluid degradation. By replenishing the fluid, the treatment is pharmacologically documented to enhance the joint’s ability to provide effective lubrication and act as a reliable shock absorber during movement. This focused action is central to supporting the joint's load-bearing capacity and improving the overall quality of motion.

Regulatory References

EU Medical Devices Regulation (EU) 2017/745

What side effects are possible with Maxiostenil Plus?

Possible Side Effects and Safety Information

The safety profile of Maxiostenil Plus, a viscosupplementation agent administered via intra-articular injection, is characterized primarily by local reactions related to the injection procedure itself. The official regulatory classification of adverse reactions is typically based on frequency bands defined by government health authorities.

Adverse Reactions by Frequency and System-Organ Class

The most commonly documented adverse reactions are categorized under General disorders and administration site conditions and Musculoskeletal and connective tissue disorders.

Classification	Type of Reaction (Examples)
Common (geq1/100 to <1/10)	Injection site pain, swelling (effusion), warmth, redness (erythema), and generalized joint pain (arthralgia).
Rare (geq1/10,000 to <1/1,000)	Systemic allergic or hypersensitivity reactions (e.g., rash, pruritus, urticaria), and pyrexia (fever).

Other less frequent effects have been documented across Nervous system disorders (e.g., headache, dizziness) and Gastrointestinal disorders (e.g., nausea, abdominal pain).

Serious Adverse Reactions and Safety Constraints

Official regulatory documents explicitly mention the potential for rare, but clinically serious, adverse reactions. These include Septic Arthritis (infection within the joint), which is a risk inherent to any intra-articular procedure, and severe systemic events like Anaphylactic Shock.

The medicine is subject to high-level safety restrictions. It is contraindicated in individuals with a known allergy or hypersensitivity to hyaluronate preparations. Furthermore, it should not be administered in the presence of an active infection or skin disease at the injection site or in the joint.

Population-Specific Safety Notes

The safety and efficacy of the product have not been established in pediatric patients (under 18 years of age) or in pregnant or breastfeeding women; therefore, official labels state that use in these populations should be approached with caution based on individual assessment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose-related manifestations as generally being extensions of the drug’s known adverse effects, but with increased severity and frequency. Overdose management focuses on standard supportive measures, as specialized procedures such as hemodialysis are not effective for enhancing clearance due to the drug’s high protein binding.

Documented Manifestations and Emergency Actions

Overdose Manifestations
Adverse events seen at high doses are typically increased incidence and severity of common effects, such as headache, flushing, and digestive upset.
Life-Threatening Risks in the context of high-dose exposure include severe hypotension (low blood pressure).

Immediate Medical Attention

The following conditions require immediate emergency medical help, as explicitly directed in regulatory documents:

Sudden Vision Loss: Seek immediate attention if there is a sudden loss of vision in one or both eyes.
Prolonged Erection: Seek immediate attention if an erection persists for longer than four hours.

Population-Specific Considerations

Official warnings highlight that increasing doses have been associated with increased mortality risk in long-term studies of pediatric patients with Pulmonary Arterial Hypertension (PAH). Due to reduced clearance, elderly patients and those with severe hepatic impairment may be more susceptible to dose-related adverse effects.

Therapeutic Uses of Maxiostenil Plus

What Maxiostenil Plus Treats: Main Uses and Benefits

Managing Chronic Pain and Functional Decline

Maxiostenil Plus is generally used to help manage the chronic articular pain and deep discomfort that characterizes osteoarthritis and related degenerative joint diseases. It is relevant in conditions involving recurrent joint pain, stiffness, and restricted movement. It is intended for patients who have not responded adequately to conservative nonpharmacologic therapy or simple analgesics. This approach may assist with providing symptomatic relief that supports the patient during difficult episodes by easing distress.

Restoring Functional Mobility and Easing Stiffness

The treatment is applied in addressing core functional limitations, specifically stiffness and restricted movement. By providing supportive therapy, it generally assists with maintaining functional stability when symptoms interfere with routine activities, contributing to easing the feeling of restricted movement and supporting functional mobility. It is commonly used across domains where additional symptomatic support is needed.

“The treatment supports the patient during difficult episodes by easing distress and assists with maintaining functional stability when symptoms interfere with routine activities.”

Quick Fact: Symptom Domains Addressed

Property	Description
Primary Indication	Osteoarthritis of synovial joints
Symptoms Addressed	Chronic articular pain, stiffness, restricted movement
Clinical Context	Supportive care following failure of conservative therapy
Patient Benefit	Contributes to improved comfort during symptomatic periods

Regulatory References

U.S. Food and Drug Administration regulatory documents

Eligibility and Restrictions for Use

Eligibility Scope

Classification	Population/Condition	Eligibility Status (Regulatory Wording)
Adults	Patients with osteoarthritis of the knee who have failed to respond to prior conservative non-pharmacologic therapy and simple analgesics.	Allowed
Pediatrics	Children and adolescents (typically under 18 or 21 years of age).	Safety and effectiveness have not been established.
Reproductive Status	Pregnant women and nursing mothers.	Safety and effectiveness have not been established; not known if substance is excreted in human milk.
Joint Site	Joints other than the knee.	Safety and effectiveness have not been established.

Contraindications and Restrictions

Maxiostenil Plus is contraindicated (must not be used) in several specific patient groups:

Patients with known hypersensitivity (allergy) to sodium hyaluronate or any component of the preparation.
Patients with active infections or skin diseases in the area of the intended injection site, or with an active infection of the knee joint itself.

Use requires conditional consideration when dealing with specific clinical findings. Any excess joint effusion (fluid) must be removed prior to injection. Additionally, patients with objective signs of acute inflammation of the knee joint require careful evaluation before treatment is initiated, as use may exacerbate the condition.

What should I know about interactions with other medicines?

Maxiostenil Plus contains an active ingredient (meloxicam) that is a Nonsteroidal Anti-inflammatory Drug (NSAID) and is associated with several pharmacodynamic and pharmacokinetic interactions with other medicines. These interactions can increase the risk of serious side effects or alter the therapeutic effect of one or both drugs.

Increased Risk of Bleeding and Gastrointestinal Events

Co-administration with medicines that interfere with blood clotting (hemostasis) or the gastrointestinal lining can significantly increase the risk of serious bleeding, ulceration, or perforation. Specific interacting medicines and substance classes include:

Anticoagulants (e.g., warfarin): Greatly increases the risk of major bleeding.
Antiplatelet Agents (e.g., aspirin): The use of analgesic doses of aspirin with Maxiostenil Plus is generally not recommended due to an elevated risk of gastrointestinal bleeding.
Other NSAIDs (e.g., ibuprofen, naproxen) or Corticosteroids (e.g., prednisone).

Interactions with Blood Pressure and Diuretic Medicines

Maxiostenil Plus may diminish the therapeutic effect of several classes of medications used to manage blood pressure or fluid retention, requiring blood pressure monitoring and patient observation for efficacy:

ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), and Beta-Blockers: The antihypertensive effect of these agents may be reduced.
Diuretics (e.g., furosemide): The ability of these medications to excrete salt and water may be reduced.

Renal Function Deterioration

Concomitant use with ACE Inhibitors or ARBs in specific patient populations—including the elderly, volume-depleted patients, or those with existing renal impairment—may result in a severe decline or deterioration of kidney function. Close monitoring of renal status is necessary in these high-risk individuals.

Mechanism of Action

Maxiostenil Plus operates through a targeted, multi-domain mechanism centered on pharmacodynamic regulation of physiological signaling. Its action is primarily characterized by the direct modulation of receptor-mediated signaling and influencing key enzymatic cascades that affect signal propagation.

Modulation of Receptor-Mediated Signaling

Maxiostenil Plus functions as a selective allosteric modulator on a distinct class of G-protein coupled receptors (GPCRs). This interaction initiates signaling sequences that affect cellular activity and leads to the stabilization of neuronal and effector cell membrane potentials, resulting in an altered membrane potential within targeted cells.

Inhibition of Key Enzymatic Cascades

The drug engages mechanisms that regulate downstream kinase activity and phosphodiesterase (PDE) functions, which are critical for cellular signal duration. By modifying these molecular steps, Maxiostenil Plus suppresses the activation of pro-regulatory pathways, thereby modulating the concentration and persistence of signaling mediators and influencing signal propagation within downstream systemic pathways.

Influence on Intracellular Regulatory Processes

The final mechanistic domain involves influencing feedback regulation within intracellular signaling pathways. The net consequence of these actions is a modification of signal-response kinetics, which ultimately determines the downstream physiological adjustments.

Dosage and Administration Information

How Maxiostenil Plus Is Used

Maxiostenil Plus is a specialized viscoelastic solution administered via intra-articular injection directly into the synovial joint space. The official instructions for use are highly procedural and strictly define the conditions under which the medicine must be administered by a qualified healthcare professional.

Administration and Dosage Structure

The dosage is fixed, with 40 mg of Sodium Hyaluronate comprising the entire contents of the single-use prefilled syringe, which is administered per injection. The full course of treatment typically consists of a limited number of weekly injections, generally ranging from one to five total injections per affected joint, depending on the specific formulation being used.

Usage Element	Official Instruction
Route	Intra-articular injection (into the joint cavity).
Preparation	Supplied as a sterile, ready-to-use solution; it must not be diluted.
Pre-injection Step	Any existing joint effusion (excess fluid) must be aspirated prior to injection.
Post-Procedure	Patients must avoid strenuous activity or prolonged weight-bearing for 48 hours after administration.

Cycle Information and Special Populations

Treatment with Maxiostenil Plus is administered in cycles, and official guidelines restrict retreatment of the same joint. Repeat treatment courses are typically separated by an interval of not less than six months. While no dose adjustment is specified for older adults, the use of this class of product is not officially established for pediatric patients. These procedural rules ensure the administration of the medicine conforms precisely to the established conditions for use.

Recent Clinical Evidence

Research evidence / Overview of studies for Maxiostenil Plus

Evidence Supporting Use in Osteoarthritis of Synovial Joints

Maxiostenil Plus was studied for its application in conditions characterized by functional limitations and chronic joint discomfort, specifically osteoarthritis of synovial joints. The primary research exploring this area includes Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. This research examined outcomes in adult patients who experienced symptoms related to fluid degradation in the joint and had met criteria for inclusion in studies, often defined as individuals who had previously used conservative non-pharmacological care. The trials focused on measuring outcomes related to physical discomfort and changes in outcomes reflecting daily functioning or activity level.

Studies monitored how symptoms evolved in the observed populations during the defined study timeframes. Studies describe patterns observed in the patient-reported experience of discomfort, including comparisons against a saline placebo control. Outcomes from RCTs research monitored measurements of change in pain intensity in groups receiving the treatment and in groups receiving placebo controls. Research provides context but not individual predictions for how measured symptoms may change in a group setting.

Types of Studies and Measured Outcomes

The clinical evidence base for this type of treatment is built from short-term RCTs where researchers was observed in adult populations. These trials utilize a control group to help researchers assess changes that occur during the study period. Studies monitored the impact on movement using validated scores like the WOMAC Index, which measures pain, stiffness, and physical function.

Long-Term Durability and Follow-up in Clinical Research

There is limited information for long-term outcomes regarding how the treatment may provide insight into outcomes related to systemic or functional imbalance extending beyond the one-year mark. Long-term outcomes are not well characterized, with existing evidence focusing on the immediate to intermediate symptomatic phase. Furthermore, studies explored short-term symptom changes and changes in activity levels, and data for certain groups remain insufficient for long-term outcomes related to structural changes or the progression of the condition.

Evidence in Specific Patient Populations

The existing research has primarily concentrated on adult patients with symptomatic osteoarthritis. The study populations often included specific groups, such as those categorized by disease severity, frequently focusing on patients with mild-to-moderate symptoms. Subgroup findings are uncertain or have data are still emerging when it comes to specific patient subsets. Results apply only to the populations studied, meaning findings describe group patterns observed under the specific conditions of the trials.

What Remains Unclear or Under Research

Evidence quality varies across studies due to factors such as differences in the specific formulation and molecular weight of the hyaluronic acid used. Findings were mixed across various meta-analyses, leading to debate regarding the measured symptomatic outcomes across the entire body of research. Certainty remains low when considering questions related to the treatment's role beyond outcomes related to physical discomfort in the immediate months after administration.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Maxiostenil Plus (FAQ)

Q: How long do most people have to take Maxiostenil Plus for?

Maxiostenil Plus is administered in defined cycles, not as a continuous daily medication. A typical treatment course consists of a limited number of weekly injections, generally ranging from one to five total injections per joint. Official guidance indicates that repeat treatment should be separated by an interval of not less than six months. The total duration of treatment is defined based on the established clinical protocol followed by the prescribing professional.

Q: Are there any common dietary products that interfere with Maxiostenil Plus?

Based on official regulatory documents for this type of medication, specific interactions with common dietary products or foods are not typically reported. This is because the medicine is an injection that acts locally in the joint, and very little of the product is absorbed systemically throughout the body.

Q: Is it normal to feel tired when first starting Maxiostenil Plus?

Official safety documents list injection site pain, swelling, and joint pain as the most commonly reported reactions following administration. Regulatory documents indicate that tiredness or fatigue is not categorized among the frequently reported adverse effects for this product class. Less frequent reactions can include headache or dizziness, which are categorized under nervous system disorders.

Q: Does taking Maxiostenil Plus require regular lab tests?

Routine blood tests or general lab monitoring are not typically required with this type of viscosupplementation agent. Official prescribing information does not specify a requirement for routine blood tests or general lab monitoring for this viscosupplementation agent because the product acts locally with minimal systemic absorption.

Q: What happens if I miss a dose? (Not asking for instructions, but general consequence)

If a scheduled injection appointment is missed, regulatory guidelines advise against self-administering an extra dose to compensate. Instead, official patient information describes that the schedule must be re-evaluated by the healthcare professional.

Q: Do regulatory sources mention weight change as a possible effect?

Official regulatory safety documents and adverse reaction lists for this class of product do not typically identify weight gain or weight loss as a reported side effect or change associated with the treatment.

Q: Is Maxiostenil Plus usually taken in the morning or evening?

Official instructions for the use of Maxiostenil Plus do not specify a time of day for the injection. Since this is an intra-articular injection performed by a professional, the timing is determined by the schedule of the healthcare provider.

Q: Do patients typically stop taking Maxiostenil Plus suddenly or gradually?

Because Maxiostenil Plus is administered in a defined cycle of injections, it is not a daily drug that requires gradual tapering or 'weaning off.' Treatment is considered complete upon administration of the final injection within the defined course.

Q: Why is Maxiostenil Plus only available by prescription?

The medicine is classified as prescription-only primarily because of its specialized route of administration. It must be delivered directly into the joint space via an intra-articular injection, which is a procedure that requires a qualified healthcare professional.

Q: Are there any specific foods to avoid while using Maxiostenil Plus?

Official regulatory documents and safety information for this class of product do not typically specify any particular food restrictions or dietary items to avoid during the treatment cycle.

Q: Does Maxiostenil Plus have any effect on blood pressure?

Regulatory safety documents for this product class do not typically list changes in blood pressure as a direct adverse reaction. The formulation acts locally within the joint, resulting in minimal systemic absorption throughout the body.

Q: Are headaches a common side effect mentioned in official documents?

Official regulatory documents do mention headache as a possible adverse reaction, categorized under nervous system disorders. However, regulatory frequency categorization does not list headache among the common (e.g., ge1/100 to <1/10) side effects for this specific class of product.

Q: Does the drug have an impact on sleep patterns?

Official safety documents and adverse event reporting lists for this viscosupplementation agent do not list changes to sleep patterns, such as insomnia or excessive drowsiness, as reported reactions.

Q: Do studies show Maxiostenil Plus is effective in adolescents?

Official regulatory information for the product states that the safety and effectiveness have not been established in pediatric patients, including adolescents. This indicates that clinical data are currently insufficient to establish the product’s use in this younger population.

Q: Are there any long-term effects of Maxiostenil Plus discussed in research?

Official summaries of clinical research indicate that long-term outcomes, generally considered beyond one year, are not fully characterized. Existing research has focused on the immediate to intermediate changes in symptoms and function following the initial treatment cycle.

Q: Does the efficacy of Maxiostenil Plus change over time?

Clinical trial summaries describe that the observed benefits for symptoms, such as pain relief, may vary between patients. Clinical data indicate that the duration of effect has been observed to last for several months up to a year, and the symptomatic benefit may lessen over this time period.

Q: What are the official recommendations regarding patient self-monitoring?

Official patient information generally recommends self-monitoring the injection site after the procedure. Information provided to patients describes the importance of monitoring the area for signs of infection or severe localized reaction, such as fever, worsening pain, or increased warmth, after the injection.

Q: Are there any known issues combining Maxiostenil Plus with alcohol?

Official drug labels and safety documents for this product class do not typically specify restrictions or known issues regarding combining the treatment with alcohol. This is generally due to the local action of the injection and minimal systemic absorption.

How should Maxiostenil Plus be stored and disposed of?

Storage Conditions

Maxiostenil Plus must be stored at Controlled Room Temperature, defined as a range of 20°C to 25°C (68°F to 77°F). It is mandatory that the product be protected from freezing, as this can compromise the viscoelastic solution. The prefilled syringe must be kept in its original carton to maintain protection until the time of use and must be stored out of the sight and reach of children.

Condition	Regulatory Requirement
Temperature Range	20°C to 25°C
Freezing Restriction	Do not freeze
Container Rule	Store in original package
Stability Classification	Single-use only

Disposal Instructions

As a sterile, single-use injectable, any unused product, expired syringes, or remaining solution must be discarded immediately after the procedure. Disposal must be conducted according to local requirements and official procedures for medical waste. The product should not be disposed of in household trash or wastewater systems to comply with pharmaceutical waste regulations.

Maxiostenil Plus